ADC Therapeutics Reports $73M Net Revenue for 2025 with Strong Cash Position
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 17h ago
0mins
Source: Newsfilter
- Financial Performance: ADC Therapeutics anticipates net product revenue of approximately $73 million for 2025, up from $69.3 million in 2024, indicating sustained market demand in the antibody-drug conjugate sector.
- Cash Flow Outlook: As of December 31, 2025, the company reported cash and cash equivalents of about $261 million, expected to support operations at least until 2028, enhancing investor confidence in financial stability.
- Clinical Progress: The company expects to complete enrollment for LOTIS-7 in the first half of 2026 and release topline data for LOTIS-5 in Q2 2026, laying the groundwork for future regulatory submissions and market introduction.
- Market Opportunities: With potential compendia inclusion in 2027 and regulatory approvals for LOTIS-5, ADC Therapeutics is poised for accelerated revenue growth, further solidifying its leadership position in the antibody-drug conjugate market.
Analyst Views on ADCT
Wall Street analysts forecast ADCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADCT is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.570
Low
5.00
Averages
7.33
High
10.00
Current: 3.570
Low
5.00
Averages
7.33
High
10.00
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
